News releases

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar “switching” or transitioning policy to expand the use of biosimilar medicines under the province’s public drug plans.

Biosimilars Canada today congratulated British Columbia and Health Minister Adrian Dix on the expansion of the province’s biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept.

Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Michel Robidoux, President and General Manager of Sandoz Canada, as Chair of the Biosimilars Canada Board. Mr. Mike Woolcock, a Senior Vice President at Apobiologix, has been unanimously re-elected as Vice-Chair of the Biosimilars Canada Board.

Member companies of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada are working with our partners in government and the pharmaceutical supply chain to mitigate shortages of medicines used in Canada’s hospitals due to increases in demand resulting from the COVID-19 outbreak.

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines.

The Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada continue to work closely with Health Canada, member companies and key stakeholders in the pharmaceutical supply chain to help ensure that Canadian patients continue to have access to high-quality generic and biosimilar medicines. To date, we are not aware of any drug shortages in Canada related to COVID-19.